Cargando…
Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine
Despite the great efforts for better treatment options for diffuse large B-cell lymphoma (DLBCL) (most common form of non-Hodgkin lymphoma, NHL) to treat and prevent relapse, it continues to be a challenge. Here, we present an overview of DLBCL and address the diagnostic assays and molecular techniq...
Autores principales: | Lodhi, Niraj, Tun, Moe, Nagpal, Poonam, Inamdar, Arati A., Ayoub, Nehad M., Siyam, Noor, Oton-Gonzalez, Lucia, Gerona, Angela, Morris, Dainelle, Sandhu, Rana, Suh, Kwangsun Stephen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646825/ https://www.ncbi.nlm.nih.gov/pubmed/33216822 http://dx.doi.org/10.18632/oncotarget.27785 |
Ejemplares similares
-
Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
por: Inamdar, Arati A., et al.
Publicado: (2016) -
The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes
por: Nagpal, Poonam, et al.
Publicado: (2020) -
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine
por: Akl, Mohamed R., et al.
Publicado: (2015) -
Synergetic effect of high dose rate radiations (10× FFF/2400 MU/min/10 MV x‐rays) and paclitaxel selectively eliminates melanoma cells
por: Lodhi, Niraj, et al.
Publicado: (2022) -
Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies
por: Akl, Mohamed R., et al.
Publicado: (2016)